Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
Date:9/22/2010

40 mcg/day

60 mcg/day

80 mcg/dayMean baseline HbA1c (%)

7.96

7.79

8.05

8.03Mean week 24 HbA1c (%)

7.07

6.93

6.67

6.67Mean HbA1c change at week 24

-0.89

-0.86

-1.38

-1.36HbA1c  < 7% at week 24

60%

71%

73%

79%Mean weight change at week 24 (lbs)

-1.8

-7.9

-6.8

-7.7"The reductions in HbA1c and weight are substantial, especially for a group of patients on metformin-only background therapy with baseline HbA1c levels at 8.0 percent.  We look forward to evaluating optimized dose regimens of ITCA 650 in broader patient populations in the phase 3 program," Graves said.

ITCA 650 therapy in the phase 2 trial was administered for the 90-day treatment period with a single insertion of ITCA 650 on day 1 and removal on or around day 90. The extension phase of the 2 trial evaluated higher doses of ITCA 650 using a single device to deliver 3 months of treatment. The phase 3 study planned for early 2011 will evaluate treatment regimens involving initial 12-week ITCA 650 dosing at 20 mcg/day transitioning to 60 mcg/day thereafter using even longer duration ITCA 650 devices.

A downloadable version of the ITCA 650 phase 2 presentation from EASD is available on the Intarcia corporate website at: http://www.intarcia.com/media_presentations.html

About ITCA 650ITCA 650 therapy for type 2 diabetes consists of DUROS continuous subcutaneous delivery of exenatide. The DUROS delivery technology comprises the DUROS device, a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy. Intarcia's proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time.

The DUROS technology can
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ROSEMONT, Ill. , Aug. 3, 2015 ... ankle problem, and you,re looking for the best possible ... for the best outcome too, and now there,s a ... there. Following steps recommended by the American Orthopaedic ... after surgery can help you avoid complications and heal ...
(Date:8/3/2015)... FRANCISCO , Aug. 3, 2015  Sage Analytics ... of portable laboratory-quality cannabis potency measurement systems, announced its ... Bay Area Cruise Fundraiser. A limited number of tickets ... festivities and help a great cause while enjoying an ... scenic cruise around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... FRANCISCO , August 3, 2015 ... size is expected to reach USD 24.7 billion ... Grand View Research Inc. Growing prevalence of neurological ... physiotherapy equipments market over the forecast period. The ... ultrasound and cryotherapy, advancement in the technologies coupled ...
Breaking Medicine Technology:Patient Guide: How to Prepare for Surgery 2Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5
... Echo Therapeutics, Inc. (OTC Bulletin Board: ... System as a non-invasive, wireless, transdermal continuous glucose monitoring ... delivery, today announced that it has raised approximately $2.5 ... Company,s stock and warrants, and it has received a ...
... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced ... officer, is scheduled to present a company overview at the ... January 13th at 11:30 a.m. PST. (Logo:   ... or the subsequent archived recording, log on to www.rigel.com ...
Cached Medicine Technology:Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 2Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 3Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million 4
(Date:8/3/2015)... Ore. (PRWEB) , ... August 03, 2015 , ... They ... Providence St. Vincent Medical Center offers some of the best care in ... M.D., neurosurgeon and neurointerventionalist, achieved the fastest average blood clot removal time in the ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of Appeals ruled in favor of the firm’s client Rebecca Hamsher, deciding that ... Medical Center must reimburse benefits for Hamsher’s residential treatment for bulimia, depression and ...
(Date:8/3/2015)... PA (PRWEB) , ... August 03, 2015 , ... ... Africa , Infectious diseases researchers from the University of Pittsburgh School of Medicine ... rollout of HIV prevention drugs in sub-Saharan Africa. , A cooperative agreement ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can ... costs. , Annually, more than 8.6 million adverse drug events are reported ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
Breaking Medicine News(10 mins):Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 2Health News:Kantor & Kantor Announces North Cypress Medical Center Must Reimburse Benefits for Mental Health Treatment 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3
... Inc.,(Nasdaq: ATRC ), a medical device company ... announced that its minimally invasive platform was,highlighted during ... techniques. On June 18, Dr. Kenneth,Ellenbogen, Vice Chairman ... Pacing at the Medical College of Virginia, chaired ...
... on MRIs with limited side effects, study found , , FRIDAY, ... to treat the "relapse-remitting" form of multiple sclerosis has been ... , Although the drug, laquinimod, is still experimental, having a ... patients. , "By and large, this doesn,t look as strong ...
... PRGO ; TASE) today announced that it ... Drug Administration to manufacture and market,Cetirizine Hydrochloride Syrup ... Consumer Healthcare,s Zyrtec(R) Syrup, 1mg/mL, indicated for the,relief ... Perrigo,s Chairman and CEO Joseph C. Papa stated, ...
... no added benefit , , THURSDAY, June 19 (HealthDay News) ... risk of HIV-1 infection in people who have sex ... finds. , Previous research has shown that herpes simplex ... of genital herpes -- increases the risk for HIV-1 ...
... Bills Delay and Fix Competitive Bidding System for ... Pete Stark,(D-CA), chair of the House Ways & ... DMEPOS Competitive Acquisition Reform,Act of 2008. Sens. Max ... member of the Senate Finance Committee, have introduced ...
... The results of a major international clinical trial coordinated ... the New England Journal of Medicine . The ... a prospective, multicentre project involving patients with heart failure ... of death in the population and associated atrial fibrillation ...
Cached Medicine News:Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 2Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 3Health News:The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France 4Health News:Experimental Drug Fights Multiple Sclerosis Activity 2Health News:Experimental Drug Fights Multiple Sclerosis Activity 3Health News:Perrigo Announces Approval for Rx Cetirizine Syrup 2Health News:Herpes Suppression May Not Prevent HIV Infection 2Health News:NCPA Statement Endorsing H.R. 6252 and S.3144 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 3
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
The revision knee system for severe joint deterioration with insufficient ligament support....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
The GENESIS II* Total Knee System will define the state of knee implants....
Medicine Products: